KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
Conditions
Myasthenia Gravis · Generalized Myasthenia Gravis
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
University of California, Irvine, Orange, California, United States
Stanford University Medical Center, Palo Alto, California, United States
University of Miami, Miami, Florida, United States
Indiana University Health, Indianapolis, Indiana, United States
University of Missouri, Columbia, Missouri, United States
Oregon Health & Science University, Portland, Oregon, United States
Contact: Study coordinator (Study Coordinatory)Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
Houston Methodist Hospital, Houston, Texas, United States
Intermountain Medical Center, Murray, Utah, United States
Westmead Institute for Medical Research, Westmead, Australia
Hospital Israelita Albert Einstein, São Paulo, Brazil
Charite- Universitätsklinikum Berlin, Berlin, Germany
Universitätsklinikum der Ruhr-Universität Bochum, Bochum, Germany
Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
Medizinische Hochscule Hannover, Hanover, Germany
Friedrich-Schiller-Universität Jena, Jena, Germany
Universitätsklinik Magdeburg, Magdeburg, Germany
Technical University Munich, Klinikum Rechts der Isar, Munich, Germany
King's Faisal Specialist Hospital and Research Center, Riyadh, Kindom of Saudi Arabia, Saudi Arabia
Cambridge University Hospital, Addenbrooke's Hospital, Cambridge, United Kingdom
King's College Hospital, London, United Kingdom
Study leads
MD
Study Director
Kyverna Therapeutics, Inc.